Monoclonal antibodies (update): CD20, rituximab


Published: June 23, 2009
Abstract Views: 166
PDF: 108
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Authors

Without any doubt, in the past 10 years Rituximab has caused a breakthrough in the prognosis of patients with both indolent and aggressive NHL. After it was shown that Rituximab as a single agent had significant activity in concert with a most favourable toxicity profile, the combination with appropriate chemotherapy showed not only an improved response rate and progression free survival, but – most strikingly – a significantly better overall survival. This has been particularly impressive in patients with advanced follicular NHL, in which group OS could not be improved during the past 30 years despite many attempts employing different treatment modalities (Marcus and Hagenbeek, 2007).

Supporting Agencies


Hagenbeek, C. (2009). Monoclonal antibodies (update): CD20, rituximab. Hematology Meeting Reports (formerly Haematologica Reports), 2(5). https://doi.org/10.4081/hmr.v2i5.728

Downloads

Citations